X AND Y TYPE ZEOLITES IN ZINC FORM AS CARRIERS FOR 6 - MERCAPTOPURINE

Marcel Jakubowski1, Mariusz Sandomierski1, Adam Voelkel1

1 Institute of Chemical Technology and Engineering, Poznan University of Technology, Poland

6-Mercaptopurine (6MP) is a drug with a different spectrum of activity. In small doses it has an anti-inflammatory effect, in higher doses it is immunosuppressive, and in the largest doses it is cytotoxic [1, 2]. This drug is used mainly in the treatment of blood cancers especially Acute Lymphoblastic Leukemia, but also in diseases such as rheumatoid arthritis, Crohn's disease, inflammatory bowel disease, systemic lupus erythematosus [3, 4, 5, 6].

The main limiting reason for the use of this drug is its poor bioavailability, which is ranges from 10% to 50%, averaging around 16%. This is because 6MP is characterized by poor water solubility (0.170 μg / ml) and a short half-life in the body. The short half-life is due to the rapid renal clearance of the compound. [1, 2, 7, 8]

One way to overcome drug delivery problems is to use carriers that release the drug in a controlled manner. Creating such carriers is a pioneering direction of science that requires a multidisciplinary approach. Current 6MP carriers are based on the creation of a disulfide bond between the carrier and the drug that is released by glutathione (GSH), sufficient amounts of which must be present in the cell to release the drug [9, 10]. Therefore, a 6MP carrier should be created, which will release the drug under the influence of body fluids. It should also release the drug gradually and be biocompatible.

In our work, for the first time, we have developed a mercaptopurine delivery system using two types of zinc zeolites. The prepared materials were characterized by a number of research techniques. All techniques confirmed the effective ion exchange in zeolites, as well as the sorption of the drug on the surface of the prepared carriers. Drug sorption studies have shown that zeolite Y retains more drug than zeolite X. Release studies performed in simulated body fluid (SBF), suggested that the drug was retained on the surface of the carriers by coordination bonds. Such bonds can be formed because 6MP has nitrogen and sulfur atoms in its structure, which have lone electron pairs capable of this type of bonds [11]. This is indicated by a gradual release of 6MP with no visible initial burst release. During the first 10 hours, both carriers released approximately 30% of retained drug. After this time, the release from the zeolite Y accelerated. This may be due to clogging of the pores in zeolite X, which are smaller than in zeolite Y. Both zeolites X and Y released large amount of drug. In our opinion this material can be used as an effective carrier for 6-mercaptopurine.


[1] M. Zacchigna, F. Cateni, G. Di Luca, S. Drioli, A simple method for the preparation of PEG-6-mercaptopurine for oral administration, Bioorganic & Medicinal Chemistry Letters, 17(23) (2007) 6607-6609.

[2] JE. Polifka, JM. Friedman, Teratogen update: azathioprine and 6-mercaptopurine, Teratology, 65(5) (2002) 240-261.

[3] J. P.M. Bökkerink, E. H. Stet, R. A. De Abreu, F. J.M. Damen, T. W. Hulscher, M. A.H. Bakker, J. A. Van Baal, 6-Mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts, Biochemical Pharmacology, 45(7) (1993) 1455-1463.

[4] S. Bhatia, W. Landier, M. Shangguan, L. Hageman, A.N. Schaible, A.R. Carter, C.L. Hanby, W. Leisenring, Y. Yasui, N.M. Kornegay, L. Mascarenhas, A.K. Ritchey, J.N. Casillas, D.S. Dickens, J. Meza, W.L. Carroll, M.V. Relling, F.L. Wong, Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group, Journal of clinical oncology, 30(17) (2012) 2094-2101.

[5] O. H. Nielsen, B. Vainer, J. Rask-Madsen, The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine, Alimentary Pharmacology & Therapeutics, 15 (2001) 1699-1708.

[6] S. Sahasranaman, D. Howard, S. Roy, Clinical pharmacology and pharmacogenetics of thiopurines, Eur J Clin Pharmacol 64 (2008) 753-767.

[7] J.-R. Wang, X. Yu, C. Zhou, Y. Lin, C. Chen, G.Pan, X. Mei, Improving the dissolution and bioavailability of 6-mercaptopurine via co-crystallization with isonicotinamide, Bioorganic & Medicinal Chemistry Letters, 25(5) (2015) 1036-1039.

[8] P. Podsiadlo, V. A. Sinani, J. H. Bahng, N. W. S. Kam, J. Lee, N. A. Kotov, Gold Nanoparticles Enhance the Anti-Leukemia Action of a 6-Mercaptopurine Chemotherapeutic Agent, Langmuir 24(2) (2008) 568-574.

[9] M. Prabaharan, J. F. Mano, Chitosan-Based Particles as Controlled Drug Delivery Systems, Drug Delivery, 12(1) (2004) 41-57.

[10] M.Gong, J. Yang, Y. Li, J. Gu, Glutathione-responsive nanoscale MOFs for effective intracellular delivery of the anticancer drug 6-mercaptopurine, Chem. Commun., 56 (2020) 6448-6451.

[11] A. A. Sharfalddin, A-H. Emwas, M. Jaremko, M. A. Hussien, Transition metal complexes of 6-mercaptopurine: Characterization, Theoretical calculation, DNA-Binding, molecular docking, and anticancer activity, Appl Organomet Chem, 35 (2021) 6041.